Capricor Therapeutics (CAPR) Revenue & Revenue Breakdown
Capricor Therapeutics Revenue Highlights
Latest Revenue (Y)
$25.18M
Latest Revenue (Q)
$3.97M
Capricor Therapeutics Revenue by Period
Capricor Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $25.18M | 887.79% |
| 2022-12-31 | $2.55M | 940.81% |
| 2021-12-31 | $244.90K | -21.06% |
| 2020-12-31 | $310.25K | -69.13% |
| 2019-12-31 | $1.01M | -39.87% |
| 2018-12-31 | $1.67M | 22.25% |
| 2017-12-31 | $1.37M | -57.14% |
| 2016-12-31 | $3.19M | -15.52% |
| 2015-12-31 | $3.78M | -21.11% |
| 2014-12-31 | $4.79M | 851.19% |
| 2013-12-31 | $503.23K | 157.41% |
| 2012-12-31 | $195.50K | -85.57% |
| 2011-12-31 | $1.35M | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | -100.00% |
| 2007-12-31 | $101.40K | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | -100.00% |
| 2003-12-31 | $2.18K | -80.98% |
| 2002-12-31 | $11.48K | 100.00% |
| 2001-12-31 | - | 100.00% |
| 2000-12-31 | - | 100.00% |
| 1999-12-31 | - | - |
Capricor Therapeutics generated $25.18M in revenue during NA 2023, up 887.79% compared to the previous quarter, and up 1506.45% compared to the same period a year ago.
Capricor Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $3.97M | -19.06% |
| 2024-03-31 | $4.91M | -59.41% |
| 2023-12-31 | $12.09M | 95.42% |
| 2023-09-30 | $6.19M | 57.90% |
| 2023-06-30 | $3.92M | 31.16% |
| 2023-03-31 | $2.99M | 211.98% |
| 2022-12-31 | $957.35K | -39.85% |
| 2022-09-30 | $1.59M | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $244.65M | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $204.08K | 400.00% |
| 2021-03-31 | $40.82K | -29.42% |
| 2020-12-31 | $57.83K | 242.94% |
| 2020-09-30 | $16.86K | -66.18% |
| 2020-06-30 | $49.86K | -73.15% |
| 2020-03-31 | $185.69K | -16.39% |
| 2019-12-31 | $222.10K | 56.33% |
| 2019-09-30 | $142.07K | -65.38% |
| 2019-06-30 | $410.35K | 78.02% |
| 2019-03-31 | $230.50K | -64.43% |
| 2018-12-31 | $648.08K | 195.59% |
| 2018-09-30 | $219.25K | -45.73% |
| 2018-06-30 | $403.96K | 0.97% |
| 2018-03-31 | $400.07K | -15.92% |
| 2017-12-31 | $475.80K | 51.88% |
| 2017-09-30 | $313.27K | -54.17% |
| 2017-06-30 | $683.59K | -22.39% |
| 2017-03-31 | $880.81K | 28.85% |
| 2016-12-31 | $683.60K | - |
| 2016-09-30 | $683.60K | -39.50% |
| 2016-06-30 | $1.13M | 23.96% |
| 2016-03-31 | $911.46K | -18.87% |
| 2015-12-31 | $1.12M | -14.56% |
| 2015-09-30 | $1.31M | 1.81% |
| 2015-06-30 | $1.29M | -27.77% |
| 2015-03-31 | $1.79M | 27.53% |
| 2014-12-31 | $1.40M | 7.72% |
| 2014-09-30 | $1.30M | 24.94% |
| 2014-06-30 | $1.04M | - |
| 2014-03-31 | $1.04M | 106.99% |
| 2013-12-31 | $503.23K | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | -100.00% |
| 2012-03-31 | $195.50K | - |
| 2011-12-31 | $195.50K | -75.95% |
| 2011-09-30 | $813.00K | 134.97% |
| 2011-06-30 | $346.00K | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Capricor Therapeutics generated $3.97M in revenue during Q2 2024, up -19.06% compared to the previous quarter, and up 132.97% compared to the same period a year ago.
Capricor Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| CDTX | Cidara Therapeutics | $63.91M | $8.46M |
| CAPR | Capricor Therapeutics | $25.18M | $3.97M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| PULM | Pulmatrix | $7.30M | $1.55M |
| FIXX | Q32 Bio | $1.16M | - |
| CBIO | Gyre Therapeutics | $794.00K | - |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| SLNO | Soleno Therapeutics | - | - |
| BPTH | Bio-Path | - | - |
| MBRX | Moleculin Biotech | - | - |
| NXTC | NextCure | - | - |
| AKTX | Akari Therapeutics | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| DFFN | CervoMed | - | - |
CAPR Revenue FAQ
What is Capricor Therapeutics’s yearly revenue?
Capricor Therapeutics's yearly revenue for 2023 was $25.18M, representing an increase of 887.79% compared to 2022. The company's yearly revenue for 2022 was $2.55M, representing an increase of 940.81% compared to 2021. CAPR's yearly revenue for 2021 was $244.9K, representing a decrease of -21.06% compared to 2020.
What is Capricor Therapeutics’s quarterly revenue?
Capricor Therapeutics's quarterly revenue for Q2 2024 was $3.97M, a -19.06% decrease from the previous quarter (Q1 2024), and a 1.38% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $4.91M, a -59.41% decrease from the previous quarter (Q4 2023), and a 64.29% increase year-over-year (Q1 2023). CAPR's quarterly revenue for Q4 2023 was $12.09M, a 95.42% increase from the previous quarter (Q3 2023), and a 1162.66% increase year-over-year (Q4 2022).
What is Capricor Therapeutics’s revenue growth rate?
Capricor Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 10181.04%, and for the last 5 years (2019-2023) was 2405.21%.